Keyword Search
Legend:
CC = Baltimore Convention Center, H = Hilton Baltimore
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Adaptive Design returned 40 record(s)
|
|
Sunday, 07/30/2017
|
An Optimized Adaptive Enrichment Design for Multi-Arm Trials
Michael Rosenblum, Johns Hopkins University; Aaron Fisher, Johns Hopkins University; Jon Steingrimsson, Johns Hopkins University; Joshua A Betz, Johns Hopkins University
2:25 PM
|
Expanding the Survey of Doctorate Recipients
Wan-Ying Chang, NSF/NCSES; Daniel Foley, NSF/NCSES; Karen Grigorian, NORC; Michael Yang, NORC; Lance Selfa, NORC
2:25 PM
|
Bayesian Interval Based Dose Finding Designs and a Web-Based Statistical Tool
Yuan Ji, NorthShore University HealthSystem/University of Chicago; Sue-Jane Wang, FDA; Shengjie Yang, NorthShore University HealthSystem
2:45 PM
|
More Information Is Better! Where Do We Get it and How Do We Use It?
Stephanie Michelle Coffey, U.S. Census Bureau; JPSM University of Maryland
4:05 PM
|
Investigation on Combining Phase II Proof-Of-Concept Trial with Dose Finding Trial
Yutao Liu, Columbia University; Qiqi Deng, Boehringer Ingelheim Pharmaceuticals, Inc.; Ken Cheung, Deptment of Biostatistics, Columbia University
4:05 PM
|
Modeling Nonresponse Bias Likelihood and Response Propensity: The Design and Implementation of Statistical Models to Identify Cases for Interventions During Data Collection
Daniel Pratt, RTI International; Jeffrey Rosen, RTI International; Michael Duprey, RTI International; Jamie Wescott, RTI International
4:20 PM
|
Adaptive Design and Statistical Consideration in Clinical Trials
Steven Sun; Grace Liu, Johnson & Johnson; Tianmeng Lyu, Univ. Minnesota Biostatistics Dept.
4:25 PM
|
Basket Trial Considerations in Phase Ib/IIa Oncology Studies of Targeted Therapy
Yihua Zhao, Boehringer Ingelheim Pharmaceuticals, Inc.
4:45 PM
|
Evaluation of Adaptive Sample Size Re-estimation (SSR) Designs:start small then ask for more?
Chaofeng Liu
5:05 PM
|
|
Monday, 07/31/2017
|
A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades
Sungjin Kim, Cedars-Sinai Medical Center; Marcio Diniz, Cedars Sinai Medical Center; Mourad Tighiouart, Cedars-Sinai Medical Center
|
Sample Size Re-Estimation and Other Midcourse Adjustments with Sequential Parallel Comparison Design
Rachel Silverman, University of North Carolina; Anastasia Ivanova, UNC at Chapel Hill
|
A Site-Adjusted Approach to the Covariate-Adjusted Response-Adaptive Allocation Design in Multi-Center Trials
Brian Di Pace, Virginia Commonwealth Univ; Roy T Sabo, Virginia Commonwealth University
10:50 AM
|
Estimators and Confidence Intervals for Adaptive Two-Stage Designs for Population Enrichment
Vladimir Dragalin, Janssen R&D; Ionut Bebu, The George Washington University
10:55 AM
|
An Embedded Experiment for Targeted Nonresponse Follow-Up in Establishment Surveys
Stephen Kaputa, U.S. Census Bureau; Katherine Thompson, U.S. Census Bureau; Jennifer Beck, National Science Foundation
11:50 AM
|
Adaptive Design by Benchmarked Sequential Sampling and Benchmarked Multiple Imputation
Shin-Jung Lee, University of Michigan
12:05 PM
|
A Simple and Flexible Graphical Approach for Adaptive Group-Sequential Clinical Trials
Frank Bretz, Novartis AG; Toshifumi Sugitani, Astellas; Willi Maurer, Novartis
2:05 PM
|
Confirmatory Group Sequential Adaptive Designs for Time-To-Event Endpoints Using a Short-Term Endpoint for Treatment Arm or Population Selection
Gernot Wassmer, Medical University of Vienna, Austria; Martin Posch, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University o; Franz Koenig, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University o; Silke Joergens, ICON Clinical Research Inc, Cologne Germany
3:05 PM
|
|
Tuesday, 08/01/2017
|
Tests and Classifications in Adaptive Designs with Applications
Qiusheng Chen, Florida State University; Xufeng Niu, Florida State University
8:35 AM
|
A Practical Bayesian Adaptive Design with Application to Cardiovascular Outcomes Trials
Matthew Psioda, UNC Chapel Hill; Joseph G Ibrahim, UNC; Mat Soukup, Center for Drug Evaluation and Research, Office of Translational Sciences, FDA
9:05 AM
|
Earning Regulatory Approval for a Phase II/III Design: a Case Study from Start to Finish
Adam Hamm, Cytel, Inc.
9:20 AM
|
Adaptive Designs in Phase II Basket Clinical Trials
Kristen Cunanan; Alexia Iasonos, Memorial Sloan Kettering Sloan Cancer Center; Ronglai Shen, Memorial Sloan Kettering Cancer Center; Colin Begg, Memorial Sloan Kettering Cancer Center; Mithat Gonen, Memorial Sloan Kettering Cancer Center
9:35 AM
|
New Adaptive Designs of Clinical Trial for Precision Medicine
Feifang Hu, George Washington University
10:35 AM
|
Statistical Considerations for an Adaptive Design for a Serious Rare Disease
Gary R Cutter, UAB School of Public Heatlh Department of Biostatistics
11:25 AM
|
Multi-Arm Multi-Stage Group Sequential Design in Clinical Trial
Pranab Ghosh, Cytel Inc, Boston University; Cyrus Mehta, Cytel Inc
11:50 AM
|
An Evaluation of Increasing Sample Size Based on Conditional Power
Michael Gaffney, Pfizer Inc.
2:05 PM
|
Efficiency Considerations for Group Sequential Designs with Adaptive Unblinded Sample Size Re-Assessment
Sam Hsiao, Cytel, Inc; Lingyun Liu, Cytel, Inc; Cyrus Mehta, Cytel Inc
2:25 PM
|
Adapting the 5-Zone Adaptive Design
Yi Liu, Takeda; Mingxiu Hu, Takeda Pharmaceutical
3:05 PM
|
Implementation of Promising Zone Methodology in a Ph 3 Trial in AML (VALOR)
Jennifer Smith, Sunesis
3:25 PM
|
|
Wednesday, 08/02/2017
|
Statistical Considerations for Rare Disease Clinical Development
Yang Song, Vertex Pharmaceuticals
|
BOP2: Bayesian Optimal Designs for Phase II Clinical Trials with Simple and Complex Endpoints
Heng Zhou, MD Anderson Cancer Center; Ying Yuan, M.D. Anderson Cancer Center
8:35 AM
|
Edit Reduction: Identifying Possible Stopping Points and Moving Toward Adaptive Design Techniques
Lisa Kaili Diamond, US Census Bureau; Justin Nguyen, U.S. Census Bureau; Brian Arthur Dumbacher, U.S. Census Bureau
11:20 AM
|
Model-based Design for the Early Development of Cancer Immunotherapy Combinations
Nolan Wages, University of Virgina
11:35 AM
|
An Optimal Covariate-Adaptive Design to Balance Tiers of Covariates
Fan Wang; Feifang Hu, George Washington University
11:50 AM
|
Practical Considerations on Simulations for Adaptive Dose Escalation and Dose Ranging Trials
Inna Perevozskaya, Glaxo SmithKline; Alun Bedding, Roche UK; Vladimir Dragalin, Janssen R&D; Parvin Fardipour, ICON
2:25 PM
|
Simulation Considerations for Multistage Adaptive Designs and Designs with Sample Size Re-Estimation: Type 1 Error Control and Beyond
Greg Cicconetti, Abbvie; Sergei Leonov, ICON Clinical Research; Yili L Pritchett, MedImmune; Michael Smith, Astellas; Alan Hartford, AbbVie
2:45 PM
|
|
|
